GlassScriptPhysician profile
Amiel Y Tokayer
NPI 1346240694
$55,735.33
in general payments reported to CMS, 2019-2025
46 companies · $4,392 in 2025
The $4,392 reported for 2025 was more than what 84% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $18K · 2021: $5,520 · 2022: $3,804 · 2023: $4,624 · 2024: $5,435 · 2025: $4,392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,379.17 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Rheumatology | $28,750.00 | 2019-2021 | |
| Abbvie INC. | $3,467.63 | 2019-2025 | Rinvoq, Skyrizi, Humira |
| Horizon Therapeutics Plc | $3,247.15 | 2019-2023 | Krystexxa |
| Amgen INC. | $3,196.44 | 2019-2025 | Tavneos, Evenity, Enbrel |
| Janssen Biotech, INC. | $2,748.53 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $2,283.08 | 2019-2025 | Cimzia, Bimzelx, Fintepla |
| Novartis Pharmaceuticals Corporation | $1,661.35 | 2019-2025 | |
| Pfizer INC. | $1,213.41 | 2019-2025 | |
| Glaxosmithkline, LLC. | $1,150.22 | 2019-2025 | Benlysta, Nucala |
| Radius Health, INC. | $1,120.05 | 2019-2025 | Tymlos |
| E.R. Squibb & Sons, L.L.C. | $1,010.77 | 2019-2025 | Orencia, Sotyktu |
| Ani Pharmaceuticals, INC. | $991.19 | 2024-2025 | Purified Cortrophin Gel |
| Astrazeneca Pharmaceuticals LP | $818.40 | 2022-2025 | Saphnelo, Fasenra |
| Lilly USA, LLC | $699.59 | 2019-2024 | Taltz |
| Genentech USA, INC. | $460.94 | 2019-2025 | Actemra |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amiel Tokayer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.